SAN FRANCISCO, May 14, 2019 /PRNewswire/
ValGenesis, a leading provider of Validation Lifecycle Management System (VLMS) software solutions, announced the opening of a new office in Munich, Germany, expanding its presence to accommodate rapid growth in Europe. The new office supports the company’s overall growth strategy and values. Led by a veteran team, ValGenesis will continue to strengthen its presence in this region to better serve customer expectations of best-in-class digital validation lifecycle solutions and delivery.
In addition to its headquarters in California, and an office in Florida, ValGenesis maintains offices in both the Netherlands and India. The company has been supporting European customers from its offices in the US for over ten years, working with some of the continent’s largest pharmaceutical and life science companies. The new office located at Neue Messe Riem in Munich places ValGenesis right at the heart of Europe, allowing the company to work more closely with customer ecosystems while enabling ValGenesis EMEA to continue in its mission to provide regional and local customers with exceptional ValGenesis VLMS implementation and technical support services. The Munich office also offers advantages for local talent acquisition and engagement of global stakeholders.
“European clients and prospects have been keen adopters of new technologies, and we are encouraged by the adoption rate we have seen in Europe, and our strengthened presence with the local pool of talent in this market will enable our customers to embrace a new digital approach to all types of validation processes,” said Mr. Robert van der Laan, Vice President of Professional Services, and Managing Director of ValGenesis EMEA.
“ValGenesis’s decision to open an office with local talent in Munich was based on increasing global demand for and adoption of its electronic Validation Lifecycle Management System. We’ve already had thousands of users working with our VLMS as a system of record across Europe, some as far back as 2010. The new office in Germany is yet another milestone for our rapidly growing company, which has increased in size by approximately fifty percent in both employee count and revenues in 2018, and is expected to grow even faster in 2019,” said Dr. Siva Samy, CEO & Chief Product Strategist of ValGenesis.
Althea D’Sylva, ValGenesis Communications, +1 510-445-0505 Ex. 1026,
ValGenesis, Inc. is the creator of an innovative software platform that serves as a foundation for managing compliance-based validation activities in life science companies. They provide the first enterprise application that manages the corporate validation lifecycle process. This solution is fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements. As the first fully paperless solution for electronic management of validation execution and approval, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award in 2005.
For more information, visit https://www.valgenesis.com